Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome

Project description

Early cancer detection for Lynch syndrome using AI

Lynch syndrome (LS) is the most common hereditary genetic condition that increases cancer risk. Historically underfunded, LS has led to inequalities in access to treatment, resulting in unnecessary cancers and deaths. The EU-funded PREDI-LYNCH project will evaluate non-invasive liquid biopsy technologies for early cancer detection in the three most common LS-associated cancers. Using AI, the project will identify cancer traces, making the methods adaptable to various healthcare systems. Additionally, a comprehensive framework will assess the socio-economic and ethical impacts of these technologies, ensuring alignment with societal values and healthcare needs. This project is part of the Cancer Mission cluster on Prevention and Early Detection of hereditary cancers.

Objective

We propose an ambitious yet well-conceived and deliverable pan-European, pan-cancer, pan-disciplinary, and multi-omic approach to address the pressing unmet need for an accurate, non-invasive, acceptable and cost-effective method of detecting precancerous and early-stage cancers in those individuals with Lynch syndrome (LS), the most common monogenetic increased hereditary cancer risk. LS has historically been underfunded and underserved, leading to significant an inequality in access and treatment. As a result, LS carriers have suffered needless cancers and deaths as a result. Our consortium has brought together the leading European experts, biotechnology companies and patient advocates to guarantee deliver practice-changing results that can be rapidly upscaled and adopted across the European Union and globally. Using an innovative clinical trial design, we will evaluate several multiple promising, non-invasive, liquid biopsy-based technologies in the three most common LS cancer types for an early-stage cancers detection. By leveraging Artificial intelligence (AI), we will identify traces of cancer, ensuring applicability to diverse healthcare systems. A comprehensive framework will assess the broader socio-economic and ethical impacts, ensuring that the solutions align with the societal values and healthcare needs. Parterning with leading biomarker companies (GNT, MSInsight, MSICare, MSIPlus and Elypta), we aim to deliver a multi-omic solution for affordable, accessible and effective test to advance the detection of heritable cancer detections in LS. This action is part of the Cancer Mission cluster of projects on “Prevention & early detection (early detection heritable cancers).

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-IA - HORIZON Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-MISS-2024-CANCER-01

See all projects funded under this call

Coordinator

OSLO UNIVERSITETSSYKEHUS HF
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 303 391,25
Address
KIRKEVEIEN 166 TARNBYGGET
0450 OSLO
Norway

See on map

Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 303 391,25

Participants (26)

Partners (1)

My booklet 0 0